Yvette Y. Leung

St. Paul's Hospital
Vancouver, BC, Canada

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 50 publications

Nationalization of clinical care pathways for inflammatory bowel disease management in Canada.

Nationalization of clinical care pathways for inflammatory bowel disease management in Canada.

Journal: Journal of the Canadian Association of Gastroenterology

Published: August 05, 2026

Proactive Fecal Calprotectin Home Monitoring in Ulcerative Colitis: Results of a Prospective Randomized Control Trial.

Proactive Fecal Calprotectin Home Monitoring in Ulcerative Colitis: Results of a Prospective Randomized Control Trial.

Journal: Gastroenterology

Published: November 01, 2025

Comparable remission and health care use in real-world inflammatory bowel disease patients initiating originator biologics vs biosimilars.

Comparable remission and health care use in real-world inflammatory bowel disease patients initiating originator biologics vs biosimilars.

Journal: World journal of gastroenterology

Published: September 28, 2025

Safety of Vedolizumab in Pregnancy: An Updated Systematic Review and Comprehensive Meta-analysis.

Safety of Vedolizumab in Pregnancy: An Updated Systematic Review and Comprehensive Meta-analysis.

Journal: Journal of clinical gastroenterology

Published: August 18, 2025

A novel inflammatory bowel disease registry powered by artificial intelligence and natural language processing.

A novel inflammatory bowel disease registry powered by artificial intelligence and natural language processing.

Journal: PLOS digital health

Published: April 26, 2025

Gut microbiome predictors of advanced therapy response in Crohn's disease: protocol for the OPTIMIST prospective, longitudinal, observational pilot study in Canada.

Gut microbiome predictors of advanced therapy response in Crohn's disease: protocol for the OPTIMIST prospective, longitudinal, observational pilot study in Canada.

Journal: BMJ open

Published: March 13, 2025

Drug Discontinuation and Persistent Symptoms Among Initiators of Bio-Originator and Biosimilar anti-Tumor Necrosis Factor Drugs in Inflammatory Bowel Disease: Real-World Contemporary Data From the CAnadian Network for Advanced Interdisciplinary Methods/CIRC Registry.

Drug Discontinuation and Persistent Symptoms Among Initiators of Bio-Originator and Biosimilar anti-Tumor Necrosis Factor Drugs in Inflammatory Bowel Disease: Real-World Contemporary Data From the CAnadian Network for Advanced Interdisciplinary Methods/CIRC Registry.

Journal: Gastro hep advances

Published: March 02, 2025

Effectiveness and Safety of Advanced Combination Treatment in Patients With Refractory Inflammatory Bowel Disease or Concomitant Immune-Mediated Disease or Extraintestinal Manifestations: A Multicenter Canadian Study.

Effectiveness and Safety of Advanced Combination Treatment in Patients With Refractory Inflammatory Bowel Disease or Concomitant Immune-Mediated Disease or Extraintestinal Manifestations: A Multicenter Canadian Study.

Journal: The American journal of gastroenterology

Published: January 20, 2025

Pregnant Pause? Not for IBD Care-A Single Tertiary Care Center Prospective Cohort Study Affirming IBD Management in Pregnancy.

Pregnant Pause? Not for IBD Care-A Single Tertiary Care Center Prospective Cohort Study Affirming IBD Management in Pregnancy.

Journal: Crohn's & colitis 360

Published: November 24, 2024

Motivations behind complementary and alternative medicine use in patients with Crohn's disease and ulcerative colitis.

Motivations behind complementary and alternative medicine use in patients with Crohn's disease and ulcerative colitis.

Journal: Journal of the Canadian Association of Gastroenterology

Published: October 17, 2024

Real-world experience and long-term outcomes of a mandatory non-medical switch of adalimumab originator to biosimilars in inflammatory bowel disease.

Real-world experience and long-term outcomes of a mandatory non-medical switch of adalimumab originator to biosimilars in inflammatory bowel disease.

Journal: World journal of gastroenterology

Published: September 02, 2024

Outcomes of a mandatory non-medical switch of infliximab to a biosimilar for inflammatory bowel disease in British Columbia, Canada.

Outcomes of a mandatory non-medical switch of infliximab to a biosimilar for inflammatory bowel disease in British Columbia, Canada.

Journal: Journal of the Canadian Association of Gastroenterology

Published: August 14, 2024

Showing 1-12 of 50

Last Updated: 09/26/2026